J Gynecol Oncol.  2011 Mar;22(1):3-8. 10.3802/jgo.2011.22.1.3.

Multivariate survival analysis of the patients with recurrent endometrial cancer

• Odagiri T
• Watari H
• Hosaka M
• Mitamura T
• Konno Y
• Kato T
• Kobayashi
• Sudo S
• Takeda M
• Kaneuchi M
• Sakuragi N

• KMID: 2173579
• DOI: http://doi.org/10.3802/jgo.2011.22.1.3

Abstract

OBJECTIVE
Few studies on the prognosticators of the patients with recurrent endometrial cancer after relapse have been reported in the literature. The aim of this study was to determine the prognosticators after relapse in patients with recurrent endometrial cancer who underwent primary complete cytoreductive surgery and adjuvant chemotherapy.
METHODS
Thirty-five patients with recurrent endometrial cancer were included in this retrospective analysis. The prognostic significance of several clinicopathological factors including histologic type, risk for recurrence, time to relapse after primary surgery, number of relapse sites, site of relapse, treatment modality, and complete resection of recurrent tumors were evaluated. Survival analyses were performed by Kaplan-Meier curves and the log-rank test. Independent prognostic factors were determined by multivariate Cox regression analysis.
RESULTS
Among the clinicopathological factors analyzed, histologic type (p=0.04), time to relapse after primary surgery (p=0.03), and the number of relapse sites (p=0.03) were significantly related to survival after relapse. Multivariate analysis revealed that time to relapse after primary surgery (hazard ratio, 6.8; p=0.004) and the number of relapse sites (hazard ratio, 11.1; p=0.002) were independent prognostic factors for survival after relapse. Survival after relapse could be stratified into three groups by the combination of two independent prognostic factors.
CONCLUSION
We conclude that time to relapse after primary surgery, and the number of relapse sites were independent prognostic factors for survival after relapse in patients with recurrent endometrial cancer.

Keyword

Endometrial cancer; Recurrence; Prognostic factor; Multivariate analysis

MeSH Terms

Endometrial Neoplasms
Female
Humans
Multivariate Analysis
Recurrence
Retrospective Studies
Survival Analysis*

Figure

• 

  Fig. 1 Stratificatiion of survival of patients with recurrent endometrial cancer by the combination of two independent prognostic factors. Survival after relapse with recurrent endometrial cancer was stratified into three groups according to the combination of time to relapse after primary surgery and number of relapse sites. Survival after relapse was significantly different between each group.

Reference

1. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet. 2003. 83:Suppl 1. 79–118.

2. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991. 40:55–65.

3. Hirahatake K, Hareyama H, Sakuragi N, Nishiya M, Makinoda S, Fujimoto S. A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma. J Surg Oncol. 1997. 65:82–87.

4. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006. 24:36–44.

5. Watari H, Todo Y, Takeda M, Ebina Y, Yamamoto R, Sakuragi N. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Gynecol Oncol. 2005. 96:651–657.

6. Watari H, Mitamura T, Moriwaki M, Hosaka M, Ohba Y, Sudo S, et al. Survival and failure pattern of patients with endometrial cancer after extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy. Int J Gynecol Cancer. 2009. 19:1585–1590.

7. Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol. 2006. 4:459–468.

8. Nishiya M, Sakuragi N, Hareyama H, Ebina Y, Furuya M, Oikawa M, et al. Cox multivariate regression models for estimating prognosis of patients with endometrioid adenocarcinoma of the uterine corpus who underwent thorough surgical staging. Int J Cancer. 1998. 79:521–525.

9. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 1987. 60:8 Suppl. 2035–2041.

10. Karagol H, Saip P, Uygun K, Kucucuk S, Aydiner A, Topuz E. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma. Med Oncol. 2006. 23:543–548.

11. Sartori E, Laface B, Gadducci A, Maggino T, Zola P, Landoni F, et al. Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study. Int J Gynecol Cancer. 2003. 13:458–465.

12. Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol. 2007. 62:28–34.

13. Burger RA, Brady MF, Bookman MA, Walker JL, Homesley HD, Fowler J, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol. 2010. 28:18 Suppl. LBA1.

14. Watari H, Xiong Y, Hassan MK, Sakuragi N. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecol Oncol. 2009. 112:229–234.

15. Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, et al. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res. 2005. 11:7243–7254.

16. Espinoza I, Lupu R. Cyr61 expression promotes taxol resistance: a molecular link with p53 in breast. Cancer Res. 2009. 69:24 Suppl. Abstract nr 1139.

17. Campagnutta E, Giorda G, De Piero G, Sopracordevole F, Visentin MC, Martella L, et al. Surgical treatment of recurrent endometrial carcinoma. Cancer. 2004. 100:89–96.

18. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010. 375:1165–1172.

19. Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008. 109:11–18.